J Neuroimmune Pharmacol 10:3544 Hoss AG, Labadorf A, Beach TG, Latourelle JC, Myers RH (2016) microRNA Profiles in Parkinsons Disease Prefrontal Cortex
In simple terms, it determines which raw ingredients (bulk drug substances) can be legally used to create compounded medications when a patient needs a customized formulation and there is no suitable FDA-approved product available
IL-6 modulation (palmitoyl tetrapeptide-7): The second Matrixyl 3000 component, Pal-GQPR, is studied for its effects on IL-6 and other inflammatory mediators in skin aging models
Morel, L
To examine whether p21 expression was sufficient to fully recapitulate the functions of p53 in ferroptosis suppression in HT-1080 cells, we generated cell lines expressing Flag-tagged CDKN1A under the control of a doxycycline (Dox)-inducible promoter, denoted p21 Dox
* These statements have not been evaluated by the Food and Drug Administration (FDA)